NCT04328844View on ClinicalTrials.gov

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Solid Tumor, AdultNon-Hodgkin Lymphoma, AdultNSCLCMyelofibrosisUveal Melanoma
Interventions
DRUG

IOA-244

IOA-244 will be administered orally once daily (QD)

DRUG

Avelumab Injection

Avelumab will be administered IV every 2 weeks

DRUG

Pemetrexed

Pemetrexed will be administered IV every 3 weeks

DRUG

Cisplatin

Cisplatin will be administered IV every 3 weeks

DRUG

Ruxolitinib

Ruxolitinib will be administered orally twice a day (BD)

Trial Locations (3)

20089

Humanitas Research Hospital, Rozzano

53100

Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

Sponsors

Lead Sponsor

iOnctura
All Listed Sponsors
lead

iOnctura

INDUSTRY

NCT04328844 - A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | Biotech Hunter | Biotech Hunter